ALAT-2014 Chronic Obstructive Pulmonary Disease (COPD) Clinical Practice Guidelines: Questions and Answers;Guía de práctica clínica de la enfermedad pulmonar obstructiva crónica (EPOC) ALAT-2014: Preguntas y respuestas

Archivos de Bronconeumologia

Volumn 51, Issue 8, 2015, Pages 403-416

  Montes de Oca, María ^a   López Varela, María Victorina ^b   Acuña, Agustín ^a   Schiavi, Eduardo ^c   Rey, María Alejandra ^b   Jardim, José ^d   Casas, Alejandro ^e   Tokumoto, Antonio ^f   Torres Duque, Carlos A ^e   Ramírez Venegas, Alejandra ^g   García, Gabriel ^h   Stirbulov, Roberto ⁱ   Camelier, Aquiles ^j   Bergna, Miguel ^k   Cohen, Mark ^l   Guzmán, Santiago ^m   Sánchez, Efraín ^a  

^a HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^c Directora del departamento de EPID   (Argentina)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e FUNDACIÓN NEUMOLÓGICA COLOMBIANA   (Colombia)

^f Servicio de Geriatría del Hospital de la Fuerza Aérea del Perú   (Peru)

^g INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^h Hospital Prof Rodolfo Rossi La Plata   (Argentina)

ⁱ FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^j ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^k Hospital Zonal de Agudos y Cronicos Dr Antonio A Cetrangolo   (Argentina)

^l Centro Medico Hospital   (Guatemala)

^m Los Magallanes   (Venezuela)

more..

Author keywords

Chronic obstructive pulmonary disease (COPD); Clinical practice guideline

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; PREDNISONE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DISEASE EXACERBATION; DRUG EFFECT; DYSPNEA; HUMAN; MONOTHERAPY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; SEX DIFFERENCE; SYSTEMIC THERAPY; TOBACCO; TREATMENT PLANNING; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; FEMALE; MALE; MASS SCREENING; OPPORTUNISTIC INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX RATIO; SMOKING; VACCINATION; CLINICAL EFFECTIVENESS; PNEUMONIA; POPULATION RISK; RISK ASSESSMENT; SCREENING TEST; SMOKING HABIT;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANTIBIOTIC PROPHYLAXIS; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGIC STUDIES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MASS SCREENING; MUSCARINIC ANTAGONISTS; OPPORTUNISTIC INFECTIONS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEX DISTRIBUTION; SMOKING; VACCINATION;

EID: 84938290468     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2015.05.024     Document Type: Article

References (119)

1. Guyatt G.H., Oxman A.D., Kunz R., Atkins D., Brozek J., Vist G., et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011, 64:395-400.
2. Glasziou P., del Mar C., Salisbury J. Evidence-Based Medicine Workbook. Finding and Applying the Best Evidence to Improve Patient Care 2003, BMJ Books, London.
3. Guyatt G., Gutterman D., Baumann M.H., Addrizzo-Harris D., Hylek E.M., Phillips B., et al. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an American College of Chest Physicians Task Force. Chest. 2006, 129:174-181.
4. Salvi S.S., Barnes P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009, 374:733-743.
5. Hu G., Zhou Y., Tian J., Yao W., Li J., Li B., et al. Risk of COPD from exposure to biomass smoke: A meta-analysis. Chest. 2010, 138:20-31.
6. Po J.Y.T., FitzGerald J.M., Carlsten C. Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax. 2011, 66:232-239.
7. Regalado J., Pérez-Padilla R., Sansores R., Páramo Ramirez J.I., Brauer M., Paré P., et al. The effect of biomass burning on respiratory symptoms and lung function in rural Mexican women. Am J Respir Crit Care Med. 2006, 174:901-905.
8. Ackermann-Liebrich U., Leuenberger P., Schwartz J., Schindler C., Monn C., Bolognini G., et al. Lung function and long term exposure to air pollutants in Switzerland. Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) Team. Am J Respir Crit Care Med. 1997, 155:122-129.
9. Downs S.H., Schindler C., Liu L-J.S., Keidel D., Bayer-Oglesby L., Brutsche M.H., et al. Reduced exposure to PM10 and attenuated age-related decline in lung function. N Engl J Med. 2007, 357:2338-2347.
10. Schindler C., Künzli N., Bongard J.P., Leuenberger P., Karrer W., Rapp R., et al. Short-term variation in air pollution and in average lung function among never-smokers. The Swiss Study on Air Pollution and Lung Diseases in Adults (SAPALDIA). Am J Respir Crit Care Med. 2001, 163:356-361.
11. Anderson H.R., Spix C., Medina S., Schouten J.P., Castellsague J., Rossi G., et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: Results from the APHEA project. Eur Respir J. 1997, 10:1064-1071.
12. Schwartz J. Air pollution and hospital admissions for the elderly in Detroit, Michigan. Am J Respir Crit Care Med. 1994, 150:648-655.
13. Burnett R.T., Dales R., Krewski D., Vincent R., Dann T., Brook J.R. Associations between ambient particulate sulphate and admissions to Ontario hospitals for cardiac and respiratory diseases. Am J Epidemiol. 1995, 142:15-22.
14. Lindberg A., Jonsson A-C., Rönmark E., Lundgren R., Larsson L-G., Lundbäck B. Ten-year cumulative incidence of COPD and risk factors for incident disease in a symptomatic cohort. Chest. 2005, 127:1544-1552.
15. Lamprecht B., McBurnie M.A., Vollmer W.M., Gudmundsson G., Welte T., Nizankowska-Mogilnicka E., et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. 2011, 139:752-763.
16. Hnizdo E., Sullivan P.A., Bang K.M., Wagner G. Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2002, 156:738-746.
17. Jordan R.E., Cheng K.K., Miller M.R., Adab P. Passive smoking and chronic obstructive pulmonary disease: Cross-sectional analysis of data from the Health Survey for England. BMJ Open. 2011, 1:e000153.
18. Prescott E., Bjerg A.M., Andersen P.K., Lange P., Vestbo J. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J. 1997, 10:822-827.
19. Sørheim I-C., Johannessen A., Gulsvik A., Bakke P.S., Silverman E.K., DeMeo D.L. Gender differences in COPD: Are women more susceptible to smoking effects than men?. Thorax. 2010, 65:480-485.
20. Ancochea J., Miravitlles M., García-Río F., Muñoz L., Sánchez G., Sobradillo V., et al. Infradiagnóstico de la enfermedad pulmonar obstructiva crónica en mujeres: cuantificación del problema, determinantes y propuestas de acción. Arch Bronconeumol. 2013, 49:223-229.
21. Lopez Varela M.V., Montes de Oca M., Halbert R.J., Muiño A., Perez-Padilla R., Tálamo C., et al. Sex-related differences in COPD in five Latin American cities: The PLATINO study. Eur Respir J. 2010, 36:1034-1041.
22. De Torres J.P., Casanova C., Hernández C., Abreu J., Aguirre-Jaime A., Gender Celli B.R. COPD in patients attending a pulmonary clinic. Chest. 2005, 128:2012-2016.
23. De Torres J.P., Cote C.G., López M.V., Casanova C., Díaz O., Marin J.M., et al. Sex differences in mortality in patients with COPD. Eur Respir J. 2009, 33:528-535.
24. Martinez F.J., Curtis J.L., Sciurba F., Mumford J., Giardino N.D., Weinmann G., et al. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med. 2007, 176:243-252.
25. Dransfield M.T., Washko G.R., Foreman M.G., Estepar R.S.J., Reilly J., Bailey W.C. Gender differences in the severity of CT emphysema in COPD. Chest. 2007, 132:464-470.
26. Celli B., Vestbo J., Jenkins C.R., Jones P.W., Ferguson G.T., Calverley P.M., et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med. 2011, 183:317-322.
27. Gonzalez A.V., Suissa S., Ernst P. Gender differences in survival following hospitalisation for COPD. Thorax. 2011, 66:38-42.
28. Caballero A., Torres-Duque C.A., Jaramillo C., Bolívar F., Sanabria F., Osorio P., et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008, 133:343-349.
29. Tálamo C., de Oca M.M., Halbert R., Perez-Padilla R., Jardim J.R.B., Muiño A., et al. Diagnostic labeling of COPD in five Latin American cities. Chest. 2007, 131:60-67.
30. Murphy D.E., Panos R.J. Diagnosis of COPD and clinical course in patients with unrecognized airflow limitation. Int J Chron Obstruct Pulmon Dis. 2013, 8:199-208.
31. Price D., Freeman D., Cleland J., Kaplan A., Cerasoli F. Earlier diagnosis and earlier treatment of COPD in primary care. Prim Care Respir J. 2011, 20:15-22.
32. Soriano J.B., Zielinski J., Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet. 2009, 374:721-732.
33. Lu M., Yao W., Zhong N., Zhou Y., Wang C., Chen P., et al. Asymptomatic patients of chronic obstructive pulmonary disease in China. Chin Med J (Engl). 2010, 123:1494-1499.
34. Montes de Oca M., Perez-Padilla R., Tálamo C., Halbert R.J., Moreno D., Lopez M.V., et al. Acute bronchodilator responsiveness in subjects with and without airflow obstruction in five Latin American cities: The PLATINO study. PulmPharmacolTher. 2010, 23:29-35.
35. Bednarek M., Maciejewski J., Wozniak M., Kuca P., Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008, 63:402-407.
36. Price D., Crockett A., Arne M., Garbe B., Jones R.C.M., Kaplan A., et al. Spirometry in primary care case-identification, diagnosis and management of COPD. Prim Care Respir J. 2009, 18:216-223.
37. Qaseem A., Wilt T.J., Weinberger S.E., Hanania N.A., Criner G., van der Molen T., et al. Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011, 155:179-191.
38. Scanlon P.D., Connett J.E., Waller L.A., Altose M.D., Bailey W.C., Buist A.S., et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000, 161:381-390.
39. Lin K., Watkins B., Johnson T., Rodriguez J.A., Barton M.B. Screening for chronic obstructive pulmonary disease using spirometry: Summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2008, 148:535-543.
40. Kohansal R., Martinez-Camblor P., Agustí A., Buist A.S., Mannino D.M., Soriano J.B. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009, 180:3-10.
41. Price D.B., Tinkelman D.G., Nordyke R.J., Isonaka S., Halbert R.J. Scoring system and clinical application of COPD diagnostic questionnaires. Chest. 2006, 129:1531-1539.
42. Zieliñski J., Bednarek M. Early detection of COPD in a high-risk population using spirometric screening. Chest. 2001, 119:731-736.
43. Haroon S., Adab P., Griffin C., Jordan R. Case finding for chronic obstructive pulmonary disease in primary care: A pilot randomised controlled trial. Br J Gen Pract. 2013, 63:e55-e62.
44. Jithoo A., Enright P.L., Burney P., Buist a S., Bateman E.D., Tan W.C., et al. Case-finding options for COPD: Results from the Burden of Obstructive Lung Disease study. Eur Respir J. 2013, 41:548-555.
45. Bunker J., Hermiz O., Zwar N., Dennis S.M., Vagholkar S., Crockett A., et al. Feasibility and efficacy of COPD case finding by practice nurses. Aust Fam Physician. 2009, 38:826-830.
46. Van Schayck C.P., Loozen J.M.C., Wagena E., Akkermans R.P., Wesseling G.J. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: Cross sectional case finding study. BMJ. 2002, 324:1370.
47. Jordan R.E., Lam K.H., Cheng K.K., Miller M.R., Marsh J.L., Ayres J.G., et al. Case finding for chronic obstructive pulmonary disease: A model for optimising a targeted approach. Thorax. 2010, 65:492-498.
48. Hamers R., Bontemps S., van den Akker M., Souza R., Penaforte J., Chavannes N. Chronic obstructive pulmonary disease in Brazilian primary care: Diagnostic competence and case-finding. Prim Care Respir J. 2006, 15:299-306.
49. Castillo D., Guayta R., Giner J., Burgos F., Capdevila C., Soriano J.B., et al. COPD case finding by spirometry in high-risk customers of urban community pharmacies: A pilot study. Respir Med. 2009, 103:839-845.
50. Løkke A., Ulrik C.S., Dahl R., Plauborg L., Dollerup J., Kristiansen L.C., et al. Detection of previously undiagnosed cases of COPD in a high-risk population identified in general practice. COPD. 2012, 9:458-465.
51. Ulrik C.S., Løkke A., Dahl R., Dollerup J., Hansen G., Cording P.H., et al. Early detection of COPD in general practice. Int J Chron Obstruct Pulmon Dis. 2011, 6:123-127.
52. Vandevoorde J., Verbanck S., Gijssels L., Schuermans D., Devroey D., de Backer J., et al. Early detection of COPD: A case finding study in general practice. Respir Med. 2007, 101:525-530.
53. Buffels J., Degryse J., Heyrman J., Decramer M. Office spirometry significantly improves early detection of COPD in general practice: The DIDASCO Study. Chest. 2004, 125:1394-1399.
54. Sansores R.H., Ramírez-Venegas A., Hernández-Zenteno R., Mayar-Maya M.E., Pérez-Bautista O.G., Velázquez Uncal M. Prevalence and diagnosis of chronic obstructive pulmonary disease among smokers at risk. A comparative study of case-finding vs. screening strategies. Respir Med. 2013, 107:580-586.
55. Hill K., Goldstein R.S., Guyatt G.H., Blouin M., Tan W.C., Davis L.L., et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010, 182:673-678.
56. Takahashi T., Ichinose M., Inoue H., Shirato K., Hattori T., Takishima T. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology. 2003, 8:504-508.
57. Schirnhofer L., Lamprecht B., Firlei N., Kaiser B., Buist a S., Halbert R.J., et al. Using targeted spirometry to reduce non-diagnosed chronic obstructive pulmonary disease. Respiration. 2011, 81:476-482.
58. Tinkelman D.G., Price D., Nordyke R.J., Halbert R.J. COPD screening efforts in primary care: What is the yield?. Prim Care Respir J 2007, 16:41-48.
59. Konstantikaki V., Kostikas K., Minas M., Batavanis G., Daniil Z., Gourgoulianis K.I., et al. Comparison of a network of primary care physicians and an open spirometry programme for COPD diagnosis. Respir Med. 2011, 105:274-281.
60. Cui J., Zhou Y., Tian J., Wang X., Zheng J., Zhong N., et al. A discriminant function model as an alternative method to spirometry for COPD screening in primary care settings in China. J Thorac Dis. 2012, 4:594-600.
61. Kögler H., Metzdorf N., Glaab T., Welte T. Preselection of patients at risk for COPD by two simple screening questions. Respir Med. 2010, 104:1012-1019.
62. Celli B.R., Cote C.G., Marin J.M., Casanova C., Montes de Oca M., Mendez R.A., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004, 350:1005-1012.
63. Nishimura K., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002, 121:1434-1440.
64. Puhan M.A., Garcia-Aymerich J., Frey M., terRiet G., Antó J.M., Agustí A.G., et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: The updated BODE index and the ADO index. Lancet. 2009, 374:704-711.
65. Oga T., Nishimura K., Tsukino M., Sato S., Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: Role of exercise capacity and health status. Am J Respir Crit Care Med. 2003, 167:544-549.
66. Landbo C., Prescott E., Lange P., Vestbo J., Almdal T.P. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999, 160:1856-1861.
67. Fan V.S., Curtis J.R., Tu S-P., McDonell M.B., Fihn S.D. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest. 2002, 122:429-436.
68. Mannino D.M., Reichert M.M., Davis K.J. Lung function decline and outcomes in an adult population. Am J Respir Crit Care Med. 2006, 173:985-990.
69. Van Dijk W.D., van den Bemt L., van den Haak-Rongen S., Bischoff E., van Weel C., Veen J.C., et al. Multidimensional prognostic indices for use in COPD patient care. A systematic review. Respir Res 2011, 12:151.
70. Puhan M.A., Hansel N.N., Sobradillo P., Enright P., Lange P., Hickson D., et al. Large-scale international validation of the ADO index in subjects with COPD: An individual subject data analysis of 10 cohorts. BMJ Open. 2012, 2.
71. Esteban C., Quintana J.M., Aburto M., Moraza J., Capelastegui A. A simple score for assessing stable chronic obstructive pulmonary disease. QJM. 2006, 99:751-759.
72. Kostianev S.S., Hodgev V.A., Iluchev D.H. Multidimensional system for assessment of COPD patients. Comparison with BODE index. Folia Med (Plovdiv). 2008, 50:29-38.
73. Mehrotra N., Freire A.X., Bauer D.C., Harris T.B., Newman A.B., Kritchevsky S.B., et al. Predictors of mortality in elderly subjects with obstructive airway disease: The PILE score. Ann Epidemiol. 2010, 20:223-232.
74. Soler-Cataluña J.J., Martínez-García M.A., Sánchez L.S., Tordera M.P., Sánchez P.R. Severe exacerbations and BODE index: Two independent risk factors for death in male COPD patients. Respir Med. 2009, 103:692-699.
75. Sundh J., Janson C., Lisspers K., Ställberg B., Montgomery S. The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD. Prim Care Respir J. 2012, 21:295-301.
76. Oga T., Tsukino M., Hajiro T., Ikeda A., Nishimura K. Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011, 6:521-526.
77. Williams J.E., Green R.H., Warrington V., Steiner M.C., Morgan M.D., Singh S.J. Development of the i-BODE: Validation of the incremental shuttle walking test within the BODE index. Respir Med. 2012, 106:390-396.
78. Esteban C., Arostegui I., Moraza J., Aburto M., Quintana J.M., Pérez-Izquierdo J., et al. Development of a decision tree to assess the severity and prognosis of stable COPD. Eur Respir J. 2011, 38:1294-1300.
79. Marin J.M., Alfageme I., Almagro P., Casanova C., Esteban C., Soler-Cataluña J.J., et al. Multicomponent indices to predict survival in COPD: The COCOMICS study. Eur Respir J. 2013, 42:323-332.
80. Chong J., Karner C., Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012, CD009157.
81. Rodrigo G.J., Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting β-agonists for stable COPD: A systematic review. Chest. 2012, 142:1104-1110.
82. Decramer M.L., Chapman K.R., Dahl R., Frith P., Devouassoux G., Fritscher C., et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallel-group study. Lancet Respir Med. 2013, 1:524-533.
83. Dong Y-H., Lin H-H., Shau W-Y., Wu Y-C., Chang C-H., Lai M-S. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: Systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013, 68:48-56.
84. Wise R.A., Anzueto A., Cotton D., Dahl R., Devins T., Disse B., et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013, 369:1491-1501.
85. Karner C., Cates C.J. Long-acting beta 2-agonist in addition to tiotropium versus either tiotropium or long-acting beta 2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012, CD008989.
86. Rodrigo G.J., Plaza V., Castro-Rodríguez J.a. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: A systematic review. Pulm Pharmacol Ther. 2012, 25:40-47.
87. Wang J., Jin D., Zuo P., Wang T., Xu Y., Xiong W. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: A meta-analysis. Respirology. 2011, 16:350-358.
88. Mahler D.A., d'Urzo A., Bateman E.D., Ozkan S.A., White T., Peckitt C., et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: A randomised, double-blind comparison. Thorax. 2012, 67:781-788.
89. Wedzicha J.A., Decramer M., Ficker J.H., Niewoehner D.E., Sandström T., Taylor A.F., et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double-blind, parallel-group study. Lancet Respir Med. 2013, 1:199-209.
90. Bateman E.D., Ferguson G.T., Barnes N., Gallagher N., Green Y., Henley M., et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: The SHINE study. Eur Respir J. 2013, 42:1484-1494.
91. Agusti A., Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011, 184:507-513.
92. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008, 359:1543-1554.
93. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007, 356:775-789.
94. Welsh E.J., Cates C.J., Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013, 5. CD007891.
95. Wedzicha J.A., Calverley P.M.A., Seemungal T.A., Hagan G., Ansari Z., Stockley R.A. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008, 177:19-26.
96. Karner C., Cates C.J. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta 2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011, CD009039.
97. Karner C., Cates C.J. Combination inhaled steroid and long-acting beta 2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011, CD008532.
98. Cazzola M., Andò F., Santus P., Ruggeri P., Di Marco F., Sanduzzi A., et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther. 2007, 20:556-561.
99. Jung K.S., Park H.Y., Park S.Y., Kim S.K., Kim Y-K., Shim J-J., et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: A randomized controlled study. Respir Med. 2012, 106:382-389.
100. Sehatzadeh S. Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): An evidence-based review. Ont Health Technol Assess Ser. 2012, 12:1-64.
101. Poole P.J., Chacko E., Wood-Baker R.W.B., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006, CD002733.
102. Walters J.A., Smith S., Poole P., Granger R.H., Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010, CD001390.
103. Alfageme I., Vazquez R., Reyes N., Muñoz J., Fernández A., Hernandez M., et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006, 61:189-195.
104. Cazzola M., Anapurapu S., Page C.P. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: A meta-analysis. Pulm Pharmacol Ther. 2012, 25:62-68.
105. Steurer-Stey C., Bachmann L.M., Steurer J., Tramèr M.R. Oral purified bacterial extracts in chronic bronchitis and COPD: Systematic review. Chest. 2004, 126:1645-1655.
106. Staykova T., Black P.N., Chacko E.E., Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev. 2013, CD004105.
107. Yao G-Y., Ma Y-L., Zhang M-Q., Gao Z-C. Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: A meta-analysis. Respiration. 2013, 86:254-260.
108. Donath E., Chaudhry A., Hernandez-Aya L.F., Lit L. A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with chronic obstructive pulmonary disease. Respir Med. 2013, 107:1385-1392.
109. Seemungal T.A., Wilkinson T.M., Hurst J.R., Perera W.R., Sapsford R.J., Wedzicha J.A. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008, 178:1139-1147.
110. Albert R.K., Connett J., Bailey W.C., Casaburi R., Cooper J.A.D., Criner G.J., et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011, 365:689-698.
111. Sethi S., Jones P.W., Theron M.S., Miravitlles M., Rubinstein E., Wedzicha J.A., et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010, 11:10.
112. Vollenweider D.J., Jarrett H., Steurer-Stey C.A., Garcia-Aymerich J., Puhan M.A. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012.
113. Miravitlles M., Moragas A., Hernández S., Bayona C., Llor C. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment?. Chest 2013, 144:1571-1577.
114. Singh J.M., Palda V.A., Stanbrook M.B., Chapman K.R. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. Arch Intern Med. 2002, 162:2527-2536.
115. Walters J., Wang W., Morley C., Soltani A. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012, CD006897.
116. De Jong Y.P., Uil S.M., Grotjohan H.P., Postma D.S., Kerstjens H.a.M., van den Berg J.W.K. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest. 2007, 132:1741-1747.
117. Leuppi J.D., Schuetz P., Bingisser R., Bodmer M., Briel M., Drescher T., et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: The REDUCE randomized clinical trial. JAMA. 2013, 309:2223-2231.
118. Walters J., Gibson P.G., Hannay M., Walters E. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009, CD001288.
119. Niewoehner D.E., Erbland M.L., Deupree R.H., Collins D., Gross N.J., Light R.W., et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999, 340:1941-1947.